Andrew Redfern
The University of Western Australia(AU)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Cancer Immunotherapy and Biomarkers, Phagocytosis and Immune Regulation, Pancreatic and Hepatic Oncology Research, Cancer Treatment and Pharmacology
Most-Cited Works
- → [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial(2021)1,014 cited
- → Controversies around epithelial–mesenchymal plasticity in cancer metastasis(2019)446 cited
- → PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial(2022)242 cited
- → Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial(2023)178 cited
- → Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer(2020)159 cited
- → Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2 -Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial(2018)153 cited
- → Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib(2013)151 cited
- → SLIRP, a Small SRA Binding Protein, Is a Nuclear Receptor Corepressor(2006)131 cited
- → [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial(2024)130 cited
- → RNA-induced silencing complex (RISC) Proteins PACT, TRBP, and Dicer are SRA binding nuclear receptor coregulators(2013)128 cited